<p>Medicenna Therapeutics Corp.（多伦多证券交易所代码：MDNA - 获取免费报告）内部人士 David Hyman 于 12 月 12 日（星期五）收购了该公司 10,000 股股票。每股的平均购买成本为 1.12 加元，总价值为 11,200.00 加元。收购完成后，该内部人士在公司持有 50,000 股，价值为 56,000 加元。这笔交易代表其持股增加了 25.00%。</p>
<p>获取 <strong>Medicenna Therapeutics</strong> 的提醒：</p>
<h2>Medicenna Therapeutics 股票表现</h2>
<p>MDNA 在周一的交易中下跌了 0.01 加元，跌至 1.09 加元。该股票的交易量为 158,893 股，而其平均交易量为 61,393 股。该公司的市值为 9092 万加元，市盈率为-6.41，贝塔值为 3.31。公司当前比率为 11.40，速动比率为 4.65，债务与股本比率为 0.88。Medicenna Therapeutics Corp.的 12 个月低点为 0.78 加元，12 个月高点为 1.98 加元。该公司的 50 日简单移动平均为 1.33 加元，200 日简单移动平均为 1.09 加元。</p>
<p>Medicenna Therapeutics（多伦多证券交易所代码：MDNA - 获取免费报告）最近于 11 月 13 日（星期四）发布了季度财报。公司报告本季度每股收益（EPS）为-0.06 加元。Medicenna Therapeutics 的净利润率为-533,640.00%，股本回报率为-159.88%。分析师预计 Medicenna Therapeutics Corp.在当前年度将发布-0.37 的每股收益。</p>
<h2>关于 Medicenna Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Medicenna Therapeutics Corp 是一家总部位于加拿大的免疫肿瘤学公司。其主要业务活动是开发和商业化增强型细胞因子和超级细胞因子用于癌症治疗。该公司正在开发特异性靶向过表达于 20 种不同癌症、癌症干细胞和肿瘤微环境免疫抑制细胞的白细胞介素-4 增强型细胞因子。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，胜过 Medicenna Therapeutics</li>
<li>什么是股息冠军？如何投资于冠军</li>
<li>Vertiv 的回调：忽略噪音，购买数据</li>
<li>高股息房地产投资信托：它们是理想的多元化方式吗？</li>
<li>内部人士购买天然气股票：2 只股票值得关注</li>
<li>经济报告在成功投资策略中的作用</li>
<li>Rivian 的自动驾驶轰动改变了一切——甚至它的估值</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Medicenna Therapeutics 吗？</h2>
<p>在考虑 Medicenna Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出顶级分析师正在悄悄向客户推荐的五只股票，建议在更广泛的市场注意到之前购买……而 Medicenna Therapeutics 并不在名单上。</p>
<p>虽然 Medicenna Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

MDNAF

<p>Medicenna Therapeutics 的内部人士 David Hyman 以每股 1.12 加元购买了 10,000 股，总计 11,200 加元，使他的持股增加了 25%，达到 50,000 股。该公司的股票交易价格为 1.09 加元，市值为 9092 万加元。Medicenna 是一家加拿大免疫肿瘤公司，专注于开发癌症治疗方案。尽管净利润率和股本回报率为负，分析师预计今年每股收益为 -0.37。该股票的评级为持有，分析师更倾向于其他股票</p>

<p>Medicenna Therapeutics Corp. (TSE:MDNA - Get Free Report) insider David Hyman acquired 10,000 shares of the firm's stock in a transaction that occurred on Friday, December 12th. The shares were purchased at an average cost of C$1.12 per share, with a total value of C$11,200.00. Following the completion of the acquisition, the insider owned 50,000 shares in the company, valued at C$56,000. This trade represents a 25.00% increase in their position.</p>
<div class="lb-trans"><p>Medicenna Therapeutics Corp.（多伦多证券交易所代码：MDNA - 获取免费报告）内部人士 David Hyman 于 12 月 12 日（星期五）收购了该公司 10,000 股股票。每股的平均购买成本为 1.12 加元，总价值为 11,200.00 加元。收购完成后，该内部人士在公司持有 50,000 股，价值为 56,000 加元。这笔交易代表其持股增加了 25.00%。</p>
</div><p>Get <strong>Medicenna Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Medicenna Therapeutics</strong> 的提醒：</p>
</div><h2>Medicenna Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Medicenna Therapeutics 股票表现</h2>
</div><p>MDNA traded down C$0.01 during trading on Monday, hitting C$1.09. The stock had a trading volume of 158,893 shares, compared to its average volume of 61,393. The firm has a market cap of C$90.92 million, a PE ratio of -6.41 and a beta of 3.31. The company has a current ratio of 11.40, a quick ratio of 4.65 and a debt-to-equity ratio of 0.88. Medicenna Therapeutics Corp. has a 12 month low of C$0.78 and a 12 month high of C$1.98. The company has a 50 day simple moving average of C$1.33 and a 200-day simple moving average of C$1.09.</p>
<div class="lb-trans"><p>MDNA 在周一的交易中下跌了 0.01 加元，跌至 1.09 加元。该股票的交易量为 158,893 股，而其平均交易量为 61,393 股。该公司的市值为 9092 万加元，市盈率为-6.41，贝塔值为 3.31。公司当前比率为 11.40，速动比率为 4.65，债务与股本比率为 0.88。Medicenna Therapeutics Corp.的 12 个月低点为 0.78 加元，12 个月高点为 1.98 加元。该公司的 50 日简单移动平均为 1.33 加元，200 日简单移动平均为 1.09 加元。</p>
</div><p>Medicenna Therapeutics (TSE:MDNA - Get Free Report) last issued its quarterly earnings results on Thursday, November 13th. The company reported C($0.06) earnings per share (EPS) for the quarter. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 159.88%. Analysts expect that Medicenna Therapeutics Corp. will post -0.37 EPS for the current year.</p>
<div class="lb-trans"><p>Medicenna Therapeutics（多伦多证券交易所代码：MDNA - 获取免费报告）最近于 11 月 13 日（星期四）发布了季度财报。公司报告本季度每股收益（EPS）为-0.06 加元。Medicenna Therapeutics 的净利润率为-533,640.00%，股本回报率为-159.88%。分析师预计 Medicenna Therapeutics Corp.在当前年度将发布-0.37 的每股收益。</p>
</div><h2>About Medicenna Therapeutics</h2>
<div class="lb-trans"><h2>关于 Medicenna Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.</p>
<div class="lb-trans"><p>Medicenna Therapeutics Corp 是一家总部位于加拿大的免疫肿瘤学公司。其主要业务活动是开发和商业化增强型细胞因子和超级细胞因子用于癌症治疗。该公司正在开发特异性靶向过表达于 20 种不同癌症、癌症干细胞和肿瘤微环境免疫抑制细胞的白细胞介素-4 增强型细胞因子。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Medicenna Therapeutics</li>
<li>What Are Dividend Champions? How to Invest in the Champions</li>
<li>The Vertiv Pullback: Ignore the Noise, Buy the Data</li>
<li>High Dividend REITs: Are They an Ideal Way to Diversify?</li>
<li>Insiders Buy Natural Gas Stocks: 2 for the Watchlist</li>
<li>The Role Economic Reports Play in a Successful Investment Strategy</li>
<li>Rivian’s Autonomy Bombshell Changes Everything—Even Its Valuation</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Medicenna Therapeutics</li>
<li>什么是股息冠军？如何投资于冠军</li>
<li>Vertiv 的回调：忽略噪音，购买数据</li>
<li>高股息房地产投资信托：它们是理想的多元化方式吗？</li>
<li>内部人士购买天然气股票：2 只股票值得关注</li>
<li>经济报告在成功投资策略中的作用</li>
<li>Rivian 的自动驾驶轰动改变了一切——甚至它的估值</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Medicenna Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Medicenna Therapeutics 吗？</h2>
</div><p>Before you consider Medicenna Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Medicenna Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medicenna Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出顶级分析师正在悄悄向客户推荐的五只股票，建议在更广泛的市场注意到之前购买……而 Medicenna Therapeutics 并不在名单上。</p>
</div><p>While Medicenna Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Medicenna Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

内部人士购买：Medicenna Therapeutics（TSE:MDNA）的一位内部人士收购了 10,000 股股票